Big news week for Relmada with FDA paths and a fresh $100M raise. 💪 The stock's finally waking up, pushing past both key WMAs. RSI is warm but not screaming, and today's volume surge on an up-day feels like conviction, not just noise. This looks like the start of a real move on real catalysts. BUY the momentum. #BiotechBreakout

FDA just gave them TWO paths to approval for their bladder cancer drug? That's huge! 📈 The stock's been volatile but keeps bouncing off support around $4. The RSI is hot, but the real story is the news. This feels like a coiled spring. BUY before the crowd fully prices in this regulatory clarity. #BiotechBounce

Relmada’s stock is on a wild ride! 🎢 The recent surge (close: $0.69, up 82% in a day) screams bullish momentum, backed by massive volume (31M vs. avg). The 9-day EMA just crossed above the 21-day, a classic buy signal. But RSI at 90.7 is *deeply* overbought—profit-taking likely ahead. News mix (failed trials + new licensing) adds volatility. Short-term traders might ride the wave, but caution’s key—this could snap back hard. Hold if you’re risk-tolerant; sell if you prefer stability. 🚀⚠️